Novel findings from the Asian Lymphoma Study Group: focus on T and NK-cell lymphomas

Novel findings from the Asian Lymphoma Study Group: focus on T and NK-cell lymphomas T and NK-cell lymphomas are aggressive neoplasms with a unique epidemiological distribution, demonstrating higher prevalence in Asian countries compared to the West. Through the efforts of international collaboration, significant progress has been made especially on the biological understanding and clinical management of rare lymphoma subtypes including NK/T-cell lymphomas and monomorphic epitheliotropic intestinal T-cell lymphoma. In this review, we summarize the current status of lymphoma research conducted by the Asian Lymphoma Study Group and highlight key updates on the advancement of T and NK-cell lymphoma research. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Hematology Springer Journals

Novel findings from the Asian Lymphoma Study Group: focus on T and NK-cell lymphomas

7 pages
Read Article

Loading next page...
 
/lp/springer_journal/novel-findings-from-the-asian-lymphoma-study-group-focus-on-t-and-nk-N3YV8BEcpi
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Japanese Society of Hematology
Subject
Medicine & Public Health; Hematology; Oncology
ISSN
0925-5710
eISSN
1865-3774
D.O.I.
10.1007/s12185-018-2406-6
Publisher site
See Article on Publisher Site

Abstract

T and NK-cell lymphomas are aggressive neoplasms with a unique epidemiological distribution, demonstrating higher prevalence in Asian countries compared to the West. Through the efforts of international collaboration, significant progress has been made especially on the biological understanding and clinical management of rare lymphoma subtypes including NK/T-cell lymphomas and monomorphic epitheliotropic intestinal T-cell lymphoma. In this review, we summarize the current status of lymphoma research conducted by the Asian Lymphoma Study Group and highlight key updates on the advancement of T and NK-cell lymphoma research.

Journal

International Journal of Hematology – Springer Journals

Published: Jan 29, 2018

References

  • Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009
    Kwong, YL; Anderson, BO; Advani, R; Kim, WS; Levine, AM; Lim, ST
  • Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines
    Tan, D; Tan, SY; Lim, ST; Kim, SJ; Kim, WS; Advani, R; Kwong, YL
  • Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project
    Au, WY; Weisenburger, DD; Intragumtornchai, T; Nakamura, S; Kim, WS; Sng, I; Vose, J; Armitage, JO; Liang, R
  • Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma Study Group
    Kim, SJ; Jung, HA; Chuang, SS; Hong, H; Guo, CC; Cao, J; Hong, XN; Suzuki, R; Kang, HJ; Won, JH; Chng, WJ; Kwong, YL; Suh, C; Song, YQ; Zhu, J; Tay, K; Lim, ST; Suzumiya, J; Lin, TY; Kim, WS
  • Primary cutaneous NK/T-cell lymphoma, nasal type and CD56-positive peripheral T-cell lymphoma: a cellular lineage and clinicopathologic study of 60 patients from Asia
    Takata, K; Hong, ME; Sitthinamsuwan, P; Loong, F; Tan, SY; Liau, JY; Hsieh, PP; Ng, SB; Yang, SF; Pongpruttipan, T; Sukpanichnant, S; Kwong, YL; Hyeh Ko, Y; Cho, YT; Chng, WJ; Matsushita, T; Yoshino, T; Chuang, SS
  • Current treatment approaches for NK/T-cell lymphoma
    Yamaguchi, M; Miyazaki, K
  • The diagnosis and management of NK/T-cell lymphomas
    Tse, E; Kwong, YL
  • Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211
    Yamaguchi, M; Tobinai, K; Oguchi, M; Ishizuka, N; Kobayashi, Y; Isobe, Y; Ishizawa, K; Maseki, N; Itoh, K; Usui, N; Wasada, I; Kinoshita, T; Ohshima, K; Matsuno, Y; Terauchi, T; Nawano, S; Ishikura, S; Kagami, Y; Hotta, T; Oshimi, K
  • Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211
    Yamaguchi, M; Tobinai, K; Oguchi, M; Ishizuka, N; Kobayashi, Y; Isobe, Y; Ishizawa, K; Maseki, N; Itoh, K; Usui, N; Wasada, I; Kinoshita, T; Hotta, T; Tsukasaki, K; Oshimi, K
  • Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study
    Kim, SJ; Kim, K; Kim, BS; Kim, CY; Suh, C; Huh, J; Lee, SW; Kim, JS; Cho, J; Lee, GW; Kang, KM; Eom, HS; Pyo, HR; Ahn, YC; Ko, YH; Kim, WS
  • Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study
    Yamaguchi, M; Kwong, YL; Kim, WS; Maeda, Y; Hashimoto, C; Suh, C; Izutsu, K; Ishida, F; Isobe, Y; Sueoka, E; Suzumiya, J; Kodama, T; Kimura, H; Hyo, R; Nakamura, S; Oshimi, K; Suzuki, R
  • SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group
    Kwong, YL; Kim, WS; Lim, ST; Kim, SJ; Tang, T; Tse, E; Leung, AY; Chim, CS
  • Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma
    Kwong, YL; Kim, SJ; Tse, E; Oh, SY; Kwak, JY; Eom, HS; Do, YR; Mun, YC; Lee, SR; Shin, HJ; Suh, C; Chuang, SS; Lee, YS; Lim, ST; Izutsu, K; Suzuki, R; Relander, T; d’Amore, F; Schmitz, N; Jaccard, A; Kim, WS
  • 5-year follow-up of the SMILE phase II study for newly-diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type
    Suzuki, R; Kwong, Y; Maeda, Y; Sakai, R; Kim, W; Suh, C; Ishida, F; Izutsu, K; Isobe, Y; Maeda, T; Sueoka, E; Okoshi, Y; Takizawa, J; Kobayashi, H; Nakamura, S; Suzumiya, J; Oshimi, K; Yamaguchi, M
  • To SMILE or not: supportive care matters
    Chan, A; Tang, T; Ng, T; Shih, V; Tay, K; Tao, M; Quek, R; Lim, ST
  • Multicenter study of comparative outcomes of hematopoietic stem cell transplant for peripheral T cell lymphoma and natural killer/T-cell lymphoma
    Hwang, WY; Koh, LP; Lim, ST; Linn, YC; Loh, YS; Koh, MB; Diong, CP; Lee, JJ; Zhang, XH; Rajgor, D; Gandhi, M; Shah, A; Goh, YT
  • Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group
    Tse, E; Chan, TS; Koh, LP; Chng, WJ; Kim, WS; Tang, T; Lim, ST; Lie, AK; Kwong, YL
  • Consortium for improving survival of lymphoma study. Clinical outcomes and prognostic factors of up-front autologous stem cell transplantation in patients with extranodal natural killer/T cell lymphoma
    Yhim, HY; Kim, JS; Mun, YC; Moon, JH; Chae, YS; Park, Y; Jo, JC; Kim, SJ; Yoon, DH; Cheong, JW; Kwak, JY; Lee, JJ; Kim, WS; Suh, C; Yang, DH
  • PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase
    Kwong, YL; Chan, TSY; Tan, D; Kim, SJ; Poon, LM; Mow, B; Khong, PL; Loong, F; Au-Yeung, R; Iqbal, J; Phipps, C; Tse, E
  • A promising new regimen for the treatment of advanced extranodal NK/T cell lymphoma
    Farid, M; Yau, YW; Tay, K; Quek, R; Tao, M; Koo, GC; Loong, S; Lim, ST
  • Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma
    Ahn, HK; Kim, SJ; Hwang, DW; Ko, YH; Tang, T; Lim, ST; Kim, WS
  • A clinical overview of centrosome amplification in human cancers
    Chan, JY
  • Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose
    Venkatakrishnan, K; Kim, TM; Lin, CC; Thye, LS; Chng, WJ; Ma, B; Chen, MH; Zhou, X; Liu, H; Kelly, V; Kim, WS
  • Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin
    Kim, HK; Moon, SM; Moon, JH; Park, JE; Byeon, S; Kim, WS
  • Targeting CD38 in refractory extranodal natural killer cell-T-cell lymphoma
    Hari, P; Raj, RV; Olteanu, H
  • Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study
    Lee, J; Suh, C; Park, YH; Ko, YH; Bang, SM; Lee, JH; Lee, DH; Huh, J; Oh, SY; Kwon, HC; Kim, HJ; Lee, SI; Kim, JH; Park, J; Oh, SJ; Kim, K; Jung, C; Park, K; Kim, WS
  • Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter study
    Yang, Y; Zhang, YJ; Zhu, Y; Cao, JZ; Yuan, ZY; Xu, LM; Wu, JX; Wang, W; Wu, T; Lu, B; Zhu, SY; Qian, LT; Zhang, FQ; Hou, XR; Liu, QF; Li, YX
  • A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis
    Kim, SJ; Yoon, DH; Jaccard, A; Chng, WJ; Lim, ST; Hong, H; Park, Y; Chang, KM; Maeda, Y; Ishida, F; Shin, DY; Kim, JS; Jeong, SH; Yang, DH; Jo, JC; Lee, GW; Choi, CW; Lee, WS; Chen, TY; Kim, K; Jung, SH; Murayama, T; Oki, Y; Advani, R; d’Amore, F; Schmitz, N; Suh, C; Suzuki, R; Kwong, YL; Lin, TY; Kim, WS
  • Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type
    Ito, Y; Kimura, H; Maeda, Y; Hashimoto, C; Ishida, F; Izutsu, K; Fukushima, N; Isobe, Y; Takizawa, J; Hasegawa, Y; Kobayashi, H; Okamura, S; Kobayashi, H; Yamaguchi, M; Suzumiya, J; Hyo, R; Nakamura, S; Kawa, K; Oshimi, K; Suzuki, R
  • Risk stratification on the basis of Deauville score on PET–CT and the presence of Epstein–Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis
    Kim, SJ; Choi, JY; Hyun, SH; Ki, CS; Oh, D; Ahn, YC; Ko, YH; Choi, S; Jung, SH; Khong, PL; Tang, T; Yan, X; Lim, ST; Kwong, YL; Kim, WS
  • Extranodal NK/T-cell lymphoma: toward the identification of clinical molecular targets
    Schmitt, C; Sako, N; Bagot, M; Huang, Y; Gaulard, P; Bensussan, A
  • Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study
    Li, Z; Xia, Y; Feng, LN; Chen, JR; Li, HM; Cui, J; Cai, QQ; Sim, KS; Nairismägi, ML; Laurensia, Y; Meah, WY; Liu, WS; Guo, YM; Chen, LZ; Feng, QS; Pang, CP; Chen, LJ; Chew, SH; Ebstein, RP; Foo, JN; Liu, J; Ha, J; Khoo, LP; Chin, ST; Zeng, YX; Aung, T; Chowbay, B; Diong, CP; Zhang, F; Liu, YH; Tang, T; Tao, M; Quek, R; Mohamad, F; Tan, SY; Teh, BT; Ng, SB; Chng, WJ; Ong, CK; Okada, Y; Raychaudhuri, S; Lim, ST; Tan, W; Peng, RJ; Khor, CC; Bei, JX
  • Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma
    Jiang, L; Gu, ZH; Yan, ZX; Zhao, X; Xie, YY; Zhang, ZG; Pan, CM; Hu, Y; Cai, CP; Dong, Y; Huang, JY; Wang, L; Shen, Y; Meng, G; Zhou, JF; Hu, JD; Wang, JF; Liu, YH; Yang, LH; Zhang, F; Wang, JM; Wang, Z; Peng, ZG; Chen, FY; Sun, ZM; Ding, H; Shi, JM; Hou, J; Yan, JS; Shi, JY; Xu, L; Li, Y; Lu, J; Zheng, Z; Xue, W; Zhao, WL; Chen, Z; Chen, SJ
  • Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma
    Koo, GC; Tan, SY; Tang, T; Poon, SL; Allen, GE; Tan, L; Chong, SC; Ong, WS; Tay, K; Tao, M; Quek, R; Loong, S; Yeoh, KW; Yap, SP; Lee, KA; Lim, LC; Tan, D; Goh, C; Cutcutache, I; Yu, W; Ng, CC; Rajasegaran, V; Heng, HL; Gan, A; Ong, CK; Rozen, S; Tan, P; Teh, BT; Lim, ST
  • Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type
    Lee, S; Park, HY; Kang, SY; Kim, SJ; Hwang, J; Lee, S; Kwak, SH; Park, KS; Yoo, HY; Kim, WS; Kim, JI; Ko, YH
  • Oncogenic activation of STAT3 pathway drives PD-L1 expression in natural killer/T cell lymphoma
    Lim, ST; Song, T; Lim, JQ; Laurensia, Y; Pang, WL; Nagarajan, S; Wijaya, GC; Tan, J; Tang, T; Nairismägi, ML; Ong, CK
  • Type II enteropathy-associated T-cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group
    Tse, E; Gill, H; Loong, F; Kim, SJ; Ng, SB; Tang, T; Ko, YH; Chng, WJ; Lim, ST; Kim, WS; Kwong, YL
  • Type II enteropathy-associated T-cell lymphoma: a distinct aggressive lymphoma with frequent γδ T-cell receptor expression
    Chan, JK; Chan, AC; Cheuk, W; Wan, SK; Lee, WK; Lui, YH; Chan, WK
  • Nuclear expression of MATK is a novel marker of type II enteropathy-associated T-cell lymphoma
    Tan, SY; Ooi, AS; Ang, MK; Koh, M; Wong, JC; Dykema, K; Ngeow, J; Loong, S; Gatter, K; Tan, L; Lim, LC; Furge, K; Tao, M; Lim, ST; Loong, F; Cheah, PL; Teh, BT
  • Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8αα phenotype
    Tan, SY; Chuang, SS; Tang, T; Tan, L; Ko, YH; Chuah, KL; Ng, SB; Chng, WJ; Gatter, K; Loong, F; Liu, YH; Hosking, P; Cheah, PL; Teh, BT; Tay, K; Koh, M; Lim, ST
  • JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma
    Nairismägi, ML; Tan, J; Lim, JQ; Nagarajan, S; Ng, CC; Rajasegaran, V; Huang, D; Lim, WK; Laurensia, Y; Wijaya, GC; Li, ZM; Cutcutache, I; Pang, WL; Thangaraju, S; Ha, J; Khoo, LP; Chin, ST; Dey, S; Poore, G; Tan, LH; Koh, HK; Sabai, K; Rao, HL; Chuah, KL; Ho, YH; Ng, SB; Chuang, SS; Zhang, F; Liu, YH; Pongpruttipan, T; Ko, YH; Cheah, PL; Karim, N; Chng, WJ; Tang, T; Tao, M; Tay, K; Farid, M; Quek, R; Rozen, SG; Tan, P; Teh, BT; Lim, ST; Tan, SY; Ong, CK
  • Lymphoma Leukemia Molecular Profiling Project and the International Peripheral T-cell Lymphoma Project. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma
    Iqbal, J; Wright, G; Wang, C; Rosenwald, A; Gascoyne, RD; Weisenburger, DD; Greiner, TC; Smith, L; Guo, S; Wilcox, RA; Teh, BT; Lim, ST; Tan, SY; Rimsza, LM; Jaffe, ES; Campo, E; Martinez, A; Delabie, J; Braziel, RM; Cook, JR; Tubbs, RR; Ott, G; Geissinger, E; Gaulard, P; Piccaluga, PP; Pileri, SA; Au, WY; Nakamura, S; Seto, M; Berger, F; de Leval, L; Connors, JM; Armitage, J; Vose, J; Chan, WC; Staudt, LM
  • EBV-associated primary nodal T/NK-cell lymphoma shows distinct molecular signature and copy number changes
    Ng, SB; Chung, TH; Kato, S; Nakamura, S; Takahashi, E; Ko, YH; Khoury, JD; Yin, CC; Soong, R; Jeyasekharan, AD; Hoppe, MM; Selvarajan, V; Tan, SY; Lim, ST; Ong, CK; Nairismägi, ML; Maheshwari, P; Choo, SN; Fan, S; Lee, CK; Chuang, SS; Chng, WJ
  • Generation of non-Hodgkin lymphoma patient-derived xenografts and in depth characterization of a monomorphic epitheliotropic intestinal T-cell lymphoma model
    Nairismägi, ML; Pang, WL; Huang, D; Tan, J; Lim, JQ; Li, ZM; Ha, J; Laurensia, Y; Wijaya, GC; Ng, CY; Santoso, EG; Teh, BT; Tan, SY; Lim, ST; Ong, CK

You’re reading a free preview. Subscribe to read the entire article.

Try 2 weeks free now

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

or browse the journals available

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off

Sign up
for free
Start 14 day
Free Trial